Haemonetics (HAE) Earnings Analysis

Haemonetics (HAE) has no confirmed upcoming earnings date. Last quarter (2026-02-05) it beat with EPS 1.31 USD vs 1.27 USD est (+3.1%). It has beaten estimates in 5/6 recent quarters (83%). Trailing P/E 38.25.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does HAE next report earnings?

No confirmed upcoming earnings date is currently scheduled for HAE. This page updates as the calendar is published.

HAE earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-02-051.31 USD1.27 USD+3.1%Beat
2025-11-061.27 USD1.12 USD+13.4%Beat
2025-08-071.1 USD1.01 USD+8.9%Beat
2025-05-081.24 USD1.22 USD+1.6%Beat
2025-02-061.19 USD1.18 USD+0.8%Beat
2024-08-081.02 USD1.03 USD-1%Miss

Beat rate: 5/6 (83%) over reported quarters with consensus data.

HAE valuation and analyst view

Trailing P/E38.25
Trailing EPS2.105 USD
Price / book4.53
Dividend yield0.00%
Market cap3.50B
Analyst consensusBuy (11 buy / 10 hold / 0 sell)
Avg price target80.33 USD

Related research pages

Frequently asked questions

When is Haemonetics (HAE)'s next earnings date?

No confirmed upcoming earnings date is currently scheduled for HAE. This page updates as the calendar is published.

Did HAE beat earnings last quarter?

In its 2026-02-05 report, HAE posted EPS of 1.31 USD versus a 1.27 USD estimate — a beat of 3.1%.

What is HAE's earnings track record?

Over the last 6 reported quarters with consensus data, HAE beat estimates 5 times (83%).

What is HAE's current P/E ratio and EPS?

HAE trades at a trailing P/E of 38.25 on trailing EPS of 2.1051401869158877 USD.

What do analysts rate HAE?

Analyst consensus is "Buy" across 21 ratings (0 strong buy, 11 buy, 10 hold, 0 sell, 0 strong sell). Average 12-month price target: 80.33 USD.